Telaprevir: Looking for a sustained virologic response in hepatitis C virus infection

V. Nehra, S. A. Rizza, R. Talwani, Zelalem Temesgen

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Telaprevir, a hepatitis C virus (HCV) NS3/NS4A protease inhibitor, was recently approved by the U.S. Food and Drug Administration for the treatment of chronic HCV genotype 1 infection. When given in combination with pegylated interferon and ribavirin, it demonstrated improved efficacy over conventional pegylated interferon and ribavirin therapy. Improvement in efficacy was also noted in African American patients who traditionally respond less well to conventional anti-HCV treatment. While the role of telaprevir in the management of chronic HCV infection remains to be fully defined, its development and licensure represents an important milestone in anti-HCV therapeutics.

Original languageEnglish (US)
Pages (from-to)829-837
Number of pages9
JournalDrugs of Today
Volume47
Issue number11
DOIs
StatePublished - Nov 1 2011

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Telaprevir: Looking for a sustained virologic response in hepatitis C virus infection'. Together they form a unique fingerprint.

  • Cite this